Zuclopenthixol-induced neuroleptic malignant syndrome at rechallenge and its extrapyramidal effects. 1989

C J Kemperman
Department of Psychiatry, State University Hospital, Groningen, The Netherlands.

This is the first report of a zuclopenthixol-induced NMS. The lack of previous reports may be because the receptor-binding profile of thioxanthenes give rise to fewer extrapyramidal effects than comparable neuroleptics. It is important to know more of the relationship between the potential for induction of extrapyramidal effects and success in NMS rechallenge.

UI MeSH Term Description Entries
D009459 Neuroleptic Malignant Syndrome A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) Neuroleptic-Induced Neuroleptic Malignant Syndrome,Neuroleptic-Malignant Syndrome, Neuroleptic Induced,NMS (Neuroleptic Malignant Syndrome),NMSs (Neuroleptic Malignant Syndrome),Neuroleptic Induced Neuroleptic Malignant Syndrome,Neuroleptic Malignant Syndrome, Neuroleptic Induced,Neuroleptic Malignant Syndromes,Syndrome, Neuroleptic Malignant,Syndromes, Neuroleptic Malignant
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D003006 Clopenthixol A thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Cisordinol,Zuclopenthixol,alpha-Clopenthixol,alpha Clopenthixol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013892 Thioxanthenes Compounds with three aromatic rings in linear arrangement with a SULFUR in the center ring.

Related Publications

C J Kemperman
July 1993, The British journal of psychiatry : the journal of mental science,
C J Kemperman
August 2000, The Australian and New Zealand journal of psychiatry,
C J Kemperman
January 2007, Clinical toxicology (Philadelphia, Pa.),
C J Kemperman
December 1984, Acta psiquiatrica y psicologica de America latina,
C J Kemperman
September 1989, DICP : the annals of pharmacotherapy,
C J Kemperman
November 1993, The American journal of psychiatry,
C J Kemperman
January 2019, Journal of clinical psychopharmacology,
Copied contents to your clipboard!